SCHEMBL4293229

SCHEMBL4293229

N#Cc1cc(Cl)ccc1NC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 6/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 5/20 0.48
HSD17B10 Q99714 2/20 0.48
ALOX15 P16050 1/20 0.48
GLA P06280 1/20 0.48
HTT P42858 3/20 0.46
APAF1 O14727 1/20 0.46
LMNA P02545 3/20 0.43
SLC22A12 Q96S37 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
TSHR P16473 1/20 0.40
NLRP3 Q96P20 1/20 0.40
ATM Q13315 1/20 0.40
VCAM1 P19320 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6177644 0.85 KDM4E (0.57) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL13102688 0.83 KCNMA1 (0.60) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL404789 0.82 HPGD (0.47) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL1015889 0.82 ALDH1A1 (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL1798542 0.81 KDM4E (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL1019310 0.81 ALDH1A1 (0.50) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL4334883 0.81 SLC22A12 (0.48) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL7937682 0.81 ALDH1A1 (0.48) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL1016756 0.81 ALDH1A1 (0.56) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL22980063 0.81 ALDH1A1 (0.55) KDM4EALDH1A1HPGDGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2015088564-A1 P2X4 RECEPTOR MODULATING COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2015-06-18 WO disclosed
EP-2271624-B9 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-11-12 EP disclosed
EP-2271624-B1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-05-21 EP disclosed
US-8481569-B2 Iminopyridine derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-09 US disclosed
CN-102066327-B Iminopyridine derivatives and use thereof TAKEDA PHARMACEUTICAL 2013-05-29 CN disclosed
CN-102066327-A Iminopyridine derivatives and use thereof TAKEDA PHARMACEUTICAL 2011-05-18 CN disclosed
US-20090270393-A1 Iminopyridine Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270393-A1 Iminopyridine Derivatives and Use Thereof ADRA1D, ADRB1, ADRB2 KDM4E 3069/4885ALDH1A1 33/4885MAPT 1926/4885
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 KDM4E 1364/4885ALDH1A1 597/4885MAPT 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.